InsiderTrades.com logo

UTHR Insider Trading

Insider Ownership Percentage: 11.90%
Insider Buying (Last 12 Months): $0.00
Insider Selling (Last 12 Months): $154,564,567.87

United Therapeutics Insider Trading History Chart

This chart shows the insider buying and selling history at United Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$40M-$20M$0$20M$40MTotal Insider BuyingTotal Insider Selling

United Therapeutics Share Price & Price History

Current Price: $307.36
Price Change: ▼ Price Decrease of -4.9 (-1.57%)
As of 04/3/2025 05:00 PM ET

This chart shows the closing price history over time for UTHR up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
MayJunJulAugSepOctNovDecJanFebMar$307.36Closing price on 04/03/25:

SEC Filings (Institutional Ownership Changes) for United Therapeutics (NASDAQ:UTHR)

94.08% of United Therapeutics stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at UTHR by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table
2022202320242025$6.66Bbought$744MsoldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$5B$0$5BTotal InflowsTotal Outflows
United Therapeutics logo
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.
Read More on United Therapeutics

Today's Range

Now: $307.36
Low: $298.00
High: $312.14

50 Day Range

MA: $335.35
Low: $304.42
High: $380.78

52 Week Range

Now: $307.36
Low: $229.72
High: $417.82

Volume

431,930 shs

Average Volume

450,375 shs

Market Capitalization

$13.80 billion

P/E Ratio

13.50

Dividend Yield

N/A

Beta

0.64

Who are the company insiders with the largest holdings of United Therapeutics?

United Therapeutics' top insider shareholders include:
  1. Paul A Mahon (EVP)
  2. Tommy G Thompson (Director)
  3. James Edgemond (CFO)
  4. Nilda Mesa (Director)
  5. Judy D Olian (Director)
  6. Louis W Sullivan (Director)
  7. Christopher Causey (Director)
  8. Michael Benkowitz (COO)
  9. Raymond Dwek (Director)
  10. Christopher Patusky (Director)
  11. Martine A Rothblatt (CEO)
  12. Martine A Rothblatt (Director)
Learn More about top insider investors at United Therapeutics.